Tolvaptan (CAS 150683-30-0)
QUICK LINKS
Tolvaptan is extensively researched for its role in modulating the function of vasopressin receptors, particularly within the context of biochemical and physiological studies. This compound acts as a selective vasopressin V2 receptor antagonist, making it a subject of interest in understanding the regulation of water reabsorption in kidney tubules. The research on Tolvaptan includes exploring its binding affinity, mechanism of action at the molecular level, and its effects on aquaporin channel activities. Additionally, studies focus on the kinetics of Tolvaptan, such as its absorption, distribution, metabolism, and excretion, to better understand how it interacts within biological systems. Researchers also investigate how Tolvaptan affects osmoregulation and sodium levels in cellular models, providing valuable data for applications in broader scientific fields.
Tolvaptan (CAS 150683-30-0) References
- Tolvaptan for Fluid Management in Living Donor Liver Transplant Recipients. | Imai, S., et al. 2018. Ann Transplant. 23: 25-33. PMID: 29311539
- Tolvaptan attenuated brain edema in experimental intracerebral hemorrhage. | Tan, Q., et al. 2019. Brain Res. 1715: 41-46. PMID: 30703371
- Predictors of tolvaptan short-term response in patients with refractory ascites: A meta-analysis. | Bellos, I., et al. 2020. J Gastroenterol Hepatol. 35: 182-191. PMID: 31323125
- Tolvaptan can limit postoperative paroxysmal atrial fibrillation occurrence after open-heart surgery. | Nakamura, Y., et al. 2020. Surg Today. 50: 841-848. PMID: 31980932
- Tolvaptan treatment of cystine urolithiasis in a mouse model of cystinuria. | Bai, Y., et al. 2021. World J Urol. 39: 263-269. PMID: 32189089
- Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome. | Delbet, JD., et al. 2020. Pediatr Nephrol. 35: 1347-1350. PMID: 32232633
- Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure. | Fukuoka, H., et al. 2020. BMC Cardiovasc Disord. 20: 467. PMID: 33121430
- Efficacy and safety of tolvaptan after pediatric congenital heart disease surgery. | Kojima, T., et al. 2021. Heart Vessels. 36: 717-723. PMID: 33388911
- Tolvaptan in the Management of Acute Euvolemic Hyponatremia After Transsphenoidal Surgery: A Retrospective Single-Center Analysis. | Indirli, R., et al. 2021. Front Endocrinol (Lausanne). 12: 689887. PMID: 34108941
- Efficacy and safety of tolvaptan in acute heart failure patients during long-distance transportation. | Iwata, S., et al. 2022. Am J Emerg Med. 51: 58-63. PMID: 34678574
- Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study. | Estilo, A., et al. 2021. Adv Ther. 38: 5721-5736. PMID: 34693505
- Tolvaptan Reduces Extracellular Fluid per Amount of Body Fluid Reduction Less Markedly than Conventional Diuretics. | Iwatani, H., et al. 2022. Intern Med. 61: 2561-2565. PMID: 35110480
- Tolvaptan in portal hypertension: real life experience. | Tejedor, M., et al. 2023. Rev Esp Enferm Dig. 115: 206. PMID: 36093979
- Persistence of tolvaptan medication for autosomal dominant polycystic kidney disease: A retrospective cohort study using Shizuoka Kokuho Database. | Saito, R., et al. 2022. Medicine (Baltimore). 101: e30923. PMID: 36221375
- Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice. | Yan, F., et al. 2022. Eur J Histochem. 66: PMID: 36373350
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tolvaptan, 10 mg | sc-364638 | 10 mg | $122.00 | |||
Tolvaptan, 50 mg | sc-364638A | 50 mg | $612.00 |